Gold prices steady ahead of Fed decision; weekly weakness noted
GUILDFORD, UK - Angle PLC (AIM:AGL, OTCQX:ANPCY), a leader in liquid biopsy technology, has announced the posting of its annual report and financial statements for the year ended December 31, 2024. The company has also released the notice for its upcoming Annual General Meeting (AGM), scheduled for 2:00 pm on Monday, June 30, 2025, at the Surrey Technology Centre in Guildford.
Shareholders are expected to receive updates about the company’s business after the formal proceedings of the AGM. Angle PLC’s board expressed anticipation in welcoming shareholders in person to discuss the company’s trajectory and future plans.
The company, known for its Parsortix® PC1 System, has been at the forefront of circulating tumor cell (CTC) solutions that are utilized across research, drug development, and clinical oncology. The Parsortix system, which is FDA cleared and patented, allows for comprehensive analysis of blood samples, including whole cell imaging and advanced molecular analysis.
Angle PLC’s commercial focus has been on clinical services and diagnostic products, with offerings that span from custom assay development to clinical trial testing for pharmaceutical companies. The Parsortix system and its related consumables and assays form the core of these products.
The company’s technology has been supported by over 100 peer-reviewed publications that vouch for the Parsortix system’s efficacy. Angle PLC’s commitment to advancing the field of liquid biopsy is reflected in its continuous innovation and the expansion of its clinical services.
This announcement is based on a press release statement and provides shareholders and the public with key information regarding the company’s upcoming AGM and the availability of its annual report. The report and AGM notice can be accessed on Angle PLC’s website.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.